PP
NAGE

Paloma Partners’s Niagen Bioscience NAGE Stock Holding History

Paloma Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-106,250
Closed -$406K – 2504
2017
Q2 		$406K Buy
+106,250
New +$337K ﹤0.01% 1660

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Paloma Partners's NAGE Position: Q3 2017 in Review

Paloma Partners sold out of Niagen Bioscience (NAGE) in Q3 2017, closing a stake of 106,250 shares — an estimated $406K sold.

Paloma Partners first reported a position in NAGE in Q2 2017 and held it in 1 quarter. The position peaked at $406K in Q2 2017. 42 funds tracked by Wall St. Rank hold NAGE as of Q3 2017.

  • Paloma Partners reported no remaining Niagen Bioscience position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 106,250 Niagen Bioscience shares in Q3 2017, an estimated $406K.
  • Paloma Partners first reported a position in Niagen Bioscience in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's Niagen Bioscience position peaked at $406K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.